Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03482167 · ClinicalTrials.gov registry record · Phase 1
NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment
A Phase 1 study, sponsored by University of Delaware.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT03482167 is a Phase 1 study that has completed, run by University of Delaware. The registered enrollment target is 64 participants.
The verdict
NCT03482167, a Phase 1 study, has completed, sponsored by University of Delaware.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities. Overall, this project has the potential to identify a novel, safe and cost-effective strategy for decreasing age-related memory loss.
Interventions
- OTHER Placebo
- DRUG Niagen®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2019-03-20 |
| Est. Completion | 2024-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03482167
The ClinicalTrials.gov registry entry for NCT03482167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Delaware, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03482167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03482167 about?
NCT03482167 is a clinical study titled "NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment". This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities. Overall, this project has the potential to identify a novel, safe and cost-effective strategy for decreasing age-related ...
What is the current status of trial NCT03482167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2019-03-20. Estimated completion is 2024-01-22.
What interventions are being tested in trial NCT03482167?
The interventions under investigation include: Placebo (OTHER), Niagen® (DRUG).
Who is sponsoring clinical trial NCT03482167?
This trial is sponsored by University of Delaware, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.